VivoSeq
Immunology

Vasculitis

47

Pipeline Programs↗

16

Active Trials↗

27

Companies Involved↗

Vasculitis is a moderately active landscape with 47 programs across 27 companies. The most active players are Veloxis Pharmaceuticals, Arog Pharmaceuticals, Inc., Mario Negri Institute for Pharmacological Research. 4 therapies are approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

22/100

Mech. Concentration

13/100

Completion Rate

61/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Veloxis Pharmaceuticals

1 program

Phase 1A

Arog Pharmaceuticals, Inc.

1 program

Phase 1Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research

1 program

Phase 1Teva logo

Teva

1 program

Phase 1Sanofi logo

Sanofi

2 programs

Phase 1AstraZeneca logo

AstraZeneca

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

73%

Small molecule

41 of 56 classified programs — the dominant modality here.

27%ALL OTHERSMonoclonal antibody814%Cell therapy47%Protein / enzyme35%

Small molecule leads; the ring shows all 56 classified programs, each share of the total. Modality classified for 98% of 59 pipeline programs.

Analysis

Trial Status

52

clinical trials

Completed17 · 33%
Unknown status8 · 15%
Terminated8 · 15%
Not yet recruiting6 · 12%
Recruiting6 · 12%
Active, not recruiting4 · 8%
Other3 · 6%

Clinical Trials

Trial Activity

52 trials

A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis
Recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT06335888·70 enrolled
A Randomized Multicenter Study for Isolated Skin Vasculitis
Recruiting·UUniversity of Pennsylvania·Phase 2·NCT02939573·90 enrolled
Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
Recruiting·HHospices Civils de Lyon·N/A·NCT03290456·146 enrolled
Prediction of Risk of Vascular Structural Damage in Patients With Large Vessel Vasculitis (LVV) Based on PET/MRA Image Evaluation System
Recruiting·NNanjing Medical University·N/A·NCT06824714·150 enrolled
Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)
Recruiting·UUniversity of Edinburgh·Phase 2·NCT06887062·60 enrolled
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT07160608·75 enrolled
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
Active, not recruiting·UUniversity of Edinburgh·Phase 2·NCT05630612·32 enrolled
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
Active, not recruiting·—·Phase 3·NCT03323476·136 enrolled
Evaluation of Glucocorticoids Plus Rituximab in Patients with Newly-Diagnosed or Relapsing IgA Vasculitis
Active, not recruiting·HHopital Foch·Phase 3·NCT05329090·75 enrolled
A Randomized, Controlled Study to Evaluate LNP023 (Iptacopan) in Patients With Active ANCA-associated Vasculitis
Active, not recruiting·Novartis logoNovartis·Phase 2·NCT06388941·84 enrolled
Telitacicept in the Treatment of Pediatric IgA Vasculitis-Associated Nephritis
Not yet recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·N/A·NCT07354503·300 enrolled
Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)
Not yet recruiting·NNovelMed Therapeutics·Phase 2·NCT06226662·12 enrolled
The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis
Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT07033299·12 enrolled
CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Not yet recruiting·MMarcela V. Maus, M.D.,Ph.D.·Phase 1/2·NCT07388277·12 enrolled
Anti-CD 19 CAR-T Cell Therapy in Patients with ANCA Vasculitis
Not yet recruiting·—·Phase 1/2·NCT06590545·8 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)